| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 552.40 | 23.4% |
| Total Income | 552.90 | 22.5% |
| Expenditure | 484.60 | 13.4% |
| PBT | 68.30 | 187.0% |
| Net Profit | 50.20 | 191.9% |
| OPM | 22.34% | 29.42pp |
| NPM | 9.08% | 5.27pp |
| EPS | 4.07 | 192.8% |
Hikal Ltd. Achieves Revenue of Rs 1860 Cr in FY25 with Improved EBITDA Margin and Strong Cashflow
14 May 2025 · 14 May 2025, 04:34 pm
Summary
Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its audited financial results for the quarter and full year ended 31st March 2025. The company reported a revenue of Rs 1860 Cr for the financial year 2025 with an EBITDA margin of 17.7%. The pharmaceutical business reported revenue growth of 20% to Rs 351 Cr and EBIT growth of 65% to Rs 55 Cr in Q4 FY25. The crop protection business reported revenue growth of 30% to Rs 201 Cr on QoQ basis and EBIT growth of 160% to Rs 36 Cr in Q4FY25.
Key Highlights
- 1
Revenue of Rs 1860 Cr in FY25
- 2
EBITDA stood at Rs 328 Cr with EBITDA margin of 17.7%
- 3
Pharmaceutical business reported revenue growth of 20% to Rs 351 Cr and EBIT growth of 65% to Rs 55 Cr in Q4 FY25
- 4
Crop protection business reported revenue growth of 30% to Rs 201 Cr on QoQ basis and EBIT growth of 160% to Rs 36 Cr in Q4FY25
- 5
Net Debt/Equity improved from 0.67 in Mar 24 to 0.59 in Mar 25
- 6
Company has recommended a final dividend of Rs 0.80 per share (40%)
- 7
CDMO business has a robust pipeline of 8 projects from both existing and potential clients
- 8
Company is focusing on capacity utilization and operational efficiency whilst aggressively building the future pipeline in the crop protection business
Management Comments
Jai Hiremath
Executive Chairman, Hikal Ltd.
Our results reflect a clear alignment to positive global trends — particularly the shift toward innovation-driven outsourcing, regulatory compliance, and demand for sustainable, niche solutions. By maintaining a sharp focus on operational excellence, expanding our global presence, and investing in differentiated capabilities, we have positioned ourselves to capitalize on emerging opportunities across both businesses.
Informational and educational content only. Not investment advice.